Sequence-specific in vivo cell targeting
AssigneesGflas Life Sciences, Inc., Seoul National University R&Db Foundation
InventorsSungyong IN, Sunghwa CHOE, Mi Jin PARK, Aiden Y. PARK, Jung Hak LIM, Dong Wook KIM, Youngdong YOO, Jongjin PARK
Life of this patent
Estimating the term…
Abstract
Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
Claims20
A method of treating cancer of a subject in need thereof, the method comprising:
- administering to the subject a chimeric polypeptide comprising a first domain comprising a sequence-specific programmable endonuclease and a second domain;
- and a guide nucleic acid comprising a sequence complementary to a target nucleic acid in a cell of the subject, wherein, upon contacting of the target nucleic acid, the chimeric polypeptide cleaves the target nucleic acid, whereby treating the cancer.
Dependencies are inferred from the claim text.